Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs Aflibercept in Recalcitrant nAMD
NCT05710471Phase 4Completed
- Sponsor
- The University of Hong Kong
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by The University of Hong Kong. Started Jul 2022; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05710471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710471.